|
|
| | BMS707035 Basic information |
| Product Name: | BMS707035 | | Synonyms: | BMS707035;2-(1,1-DIOXOTHIAZINAN-2-YL)-N-[(4-FLUOROPHENYL)METHYL]-5-HYDROXY-1-METHYL-6-OXOPYRIMIDINE-4-CARBOXAMIDE;N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-4-pyrimidinecarboxamide;4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin;CS-455;BMS 707035;BMS707035;4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-;BMS707035 USP/EP/BP | | CAS: | 729607-74-3 | | MF: | C17H19FN4O5S | | MW: | 410.42 | | EINECS: | | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 729607-74-3.mol |  |
| | BMS707035 Chemical Properties |
| density | 1.54 | | storage temp. | Store at -20°C | | solubility | insoluble in EtOH; insoluble in H2O; ≥41 mg/mL in DMSO | | form | Powder | | pka | 4.50±1.00(Predicted) |
| | BMS707035 Usage And Synthesis |
| Uses | BMS-707035 is a specific HIV-I integrase (IN) inhibitor. | | target | HIV-I integrase |
| | BMS707035 Preparation Products And Raw materials |
|